TORONTO, Nov. 2 /CNW/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical
company dedicated to the development and commercialization of cancer
therapies, announced today that its lead product candidate, Neuradiab, has
been granted orphan drug status for the treatment of glioblastoma multiforme
(GBM) by the Committee for Orphan Medicinal Products (COMP) of the European
Medicines Agency (EMEA). Bradmer has previously obtained orphan drug status
for Neuradiab from the U.S. Food and Drug Administration.
